PE20141352A1 - Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento - Google Patents
Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamentoInfo
- Publication number
- PE20141352A1 PE20141352A1 PE2014000158A PE2014000158A PE20141352A1 PE 20141352 A1 PE20141352 A1 PE 20141352A1 PE 2014000158 A PE2014000158 A PE 2014000158A PE 2014000158 A PE2014000158 A PE 2014000158A PE 20141352 A1 PE20141352 A1 PE 20141352A1
- Authority
- PE
- Peru
- Prior art keywords
- aza
- hex
- bicycle
- phenyl
- methanones
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 2
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE FENIL-3-AZA-BICICLO[3,1,0]HEX-3-IL-METANONA DE FORMULA (I) DONDE R1 ES HETEROARILO MONOCICLICO DE 5 O 6 MIEMBROS, HETEROCICLOALQUILO DE 5 O 6 MIEMBROS O HETEROARILO BICICLICO DE 9 O 10 MIEMBROS; R2 ES H, ALQUILO(C1-C4), CN, ENTRE OTROS; R3 ES ALQUILO(C1-C6)-O-, CICLOALQUIL(C3-C6)-O-, MORFOLINO, ENTRE OTROS; R4, R5 Y R7 SON CADA UNO H, ENTRE OTROS; R6 ES H, ALQUIL(C1-C4)-SO2-, CICLOALQUIL(C3-C6)-SO2- O CN. SON COMPUESTOS PREFERIDOS LOS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE GLICINA 1 (GlyT1) SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176468 | 2011-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141352A1 true PE20141352A1 (es) | 2014-10-12 |
Family
ID=46598566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000158A PE20141352A1 (es) | 2011-08-03 | 2012-08-02 | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9012489B2 (es) |
| EP (1) | EP2739615B1 (es) |
| JP (1) | JP5850589B2 (es) |
| KR (1) | KR101944686B1 (es) |
| CN (2) | CN103797005B (es) |
| AP (1) | AP2014007399A0 (es) |
| AR (1) | AR087436A1 (es) |
| AU (1) | AU2012292036C1 (es) |
| BR (1) | BR112014001642B1 (es) |
| CA (1) | CA2843805C (es) |
| CL (1) | CL2014000246A1 (es) |
| CO (1) | CO6870037A2 (es) |
| CY (1) | CY1119326T1 (es) |
| DK (1) | DK2739615T3 (es) |
| EA (1) | EA024933B1 (es) |
| EC (1) | ECSP14013221A (es) |
| ES (1) | ES2623006T3 (es) |
| GE (1) | GEP20166483B (es) |
| HR (1) | HRP20170695T1 (es) |
| HU (1) | HUE033134T2 (es) |
| IL (1) | IL229962A (es) |
| LT (1) | LT2739615T (es) |
| MA (1) | MA35286B1 (es) |
| ME (1) | ME02672B (es) |
| MX (1) | MX347828B (es) |
| MY (1) | MY167396A (es) |
| PE (1) | PE20141352A1 (es) |
| PH (1) | PH12014500276A1 (es) |
| PL (1) | PL2739615T3 (es) |
| PT (1) | PT2739615T (es) |
| RS (1) | RS55927B1 (es) |
| SI (1) | SI2739615T1 (es) |
| TN (1) | TN2014000044A1 (es) |
| TW (1) | TWI543974B (es) |
| UA (1) | UA114405C2 (es) |
| UY (1) | UY34239A (es) |
| WO (1) | WO2013017657A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10118906B2 (en) | 2014-06-06 | 2018-11-06 | Basf Se | Use of substituted oxadiazoles for combating phytopathogenic fungi |
| WO2017081309A1 (en) | 2015-11-13 | 2017-05-18 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| AR106679A1 (es) | 2015-11-13 | 2018-02-07 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatógenos |
| CN108289449A (zh) | 2015-11-19 | 2018-07-17 | 巴斯夫欧洲公司 | 用于防除植物病原性真菌的取代噁二唑 |
| US10986839B2 (en) | 2016-04-11 | 2021-04-27 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| PH12021552741A1 (en) * | 2019-05-01 | 2022-07-11 | Boehringer Ingelheim Int | Solid forms of a glyt1 inhibitor |
| CA3166938A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| BR112022026698A2 (pt) * | 2020-08-13 | 2023-02-23 | Boehringer Ingelheim Int | Tratamento da deficiência cognitiva associada à esquizofrenia |
| CN117567449A (zh) | 2020-10-13 | 2024-02-20 | 勃林格殷格翰国际有限公司 | 再加工方法 |
| WO2023097276A1 (en) * | 2021-11-24 | 2023-06-01 | Maplight Therapeutics, Inc. | Methods of treating neurological disorders |
| CN114957087A (zh) * | 2022-04-13 | 2022-08-30 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德中间体制备方法 |
| CN117597342A (zh) * | 2022-06-10 | 2024-02-23 | 成都百裕制药股份有限公司 | 吡咯烷衍生物、药物组合物及其在医药上的应用 |
| AU2023328948A1 (en) | 2022-08-24 | 2025-01-16 | Boehringer Ingelheim International Gmbh | A scalable process for the preparation of a glyt-1 inhibitor |
| WO2024243600A2 (en) * | 2023-05-25 | 2024-11-28 | Maplight Therapeutics, Inc. | Compositions for treating neurological disorders |
| WO2025140479A1 (zh) * | 2023-12-29 | 2025-07-03 | 苏州科睿思制药有限公司 | Iclepertin的晶型及其制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60313898T2 (de) * | 2003-04-10 | 2008-01-17 | Ranbaxy Laboratories, Ltd. | Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten |
| CA2542279C (en) | 2003-10-14 | 2011-08-09 | Pfizer Products Inc. | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| DE102004035280A1 (de) | 2004-07-21 | 2006-03-16 | Robert Bosch Gmbh | Kraftstoffinjektor mit direkter mehrstufiger Einspritzventilgliedansteuerung |
| RU2007125380A (ru) * | 2005-01-06 | 2009-02-20 | Ф. Хоффманн-Ля Рош Аг (Ch) | Сульфанил-замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения неврологических и психоневрологических заболеваний |
| DE602005022113D1 (de) * | 2005-01-07 | 2010-08-12 | Hoffmann La Roche | Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen |
| HRP20100076T1 (hr) * | 2005-02-07 | 2010-03-31 | F. Hoffmann - La Roche Ag | Heterociklički supstituirani fenil metanoni kao inhibitori glicin transportera 1 |
| KR101072796B1 (ko) * | 2006-06-22 | 2011-10-14 | 에프. 호프만-라 로슈 아게 | 치환된 페닐 메탄온 유도체 |
| BRPI0713381A2 (pt) | 2006-06-28 | 2012-03-13 | Amgen Inc | composto, composição farmacêutica, e, método para o tratamento de uma doença |
| TW200833328A (en) * | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| KR20110117087A (ko) * | 2008-12-29 | 2011-10-26 | 벤더르빌트 유니버시티 | 3.1.0 비시클릭 ｇｌｙｔ1 억제제 및 그것을 제조 및 사용하는 방법 |
| PE20120500A1 (es) | 2009-01-27 | 2012-05-04 | Hoffmann La Roche | Piperidinas sustituidas con heteroilamino y aroilamino como inhibidores de glyt-1 |
-
2012
- 2012-07-27 US US13/560,063 patent/US9012489B2/en active Active
- 2012-08-01 TW TW101127831A patent/TWI543974B/zh active
- 2012-08-02 JP JP2014523332A patent/JP5850589B2/ja active Active
- 2012-08-02 RS RS20170472A patent/RS55927B1/sr unknown
- 2012-08-02 PL PL12741022T patent/PL2739615T3/pl unknown
- 2012-08-02 CA CA2843805A patent/CA2843805C/en active Active
- 2012-08-02 SI SI201230968A patent/SI2739615T1/sl unknown
- 2012-08-02 AU AU2012292036A patent/AU2012292036C1/en active Active
- 2012-08-02 PH PH1/2014/500276A patent/PH12014500276A1/en unknown
- 2012-08-02 CN CN201280042794.7A patent/CN103797005B/zh active Active
- 2012-08-02 HU HUE12741022A patent/HUE033134T2/en unknown
- 2012-08-02 PE PE2014000158A patent/PE20141352A1/es active IP Right Grant
- 2012-08-02 AR ARP120102828 patent/AR087436A1/es active IP Right Grant
- 2012-08-02 GE GEAP201213402A patent/GEP20166483B/en unknown
- 2012-08-02 UA UAA201402017A patent/UA114405C2/uk unknown
- 2012-08-02 ES ES12741022.3T patent/ES2623006T3/es active Active
- 2012-08-02 MY MYPI2014000271A patent/MY167396A/en unknown
- 2012-08-02 ME MEP-2017-92A patent/ME02672B/me unknown
- 2012-08-02 AP AP2014007399A patent/AP2014007399A0/xx unknown
- 2012-08-02 HR HRP20170695TT patent/HRP20170695T1/hr unknown
- 2012-08-02 MX MX2014001252A patent/MX347828B/es active IP Right Grant
- 2012-08-02 LT LTEP12741022.3T patent/LT2739615T/lt unknown
- 2012-08-02 PT PT127410223T patent/PT2739615T/pt unknown
- 2012-08-02 WO PCT/EP2012/065140 patent/WO2013017657A1/en not_active Ceased
- 2012-08-02 BR BR112014001642-9A patent/BR112014001642B1/pt active IP Right Grant
- 2012-08-02 EA EA201400183A patent/EA024933B1/ru not_active IP Right Cessation
- 2012-08-02 EP EP12741022.3A patent/EP2739615B1/en active Active
- 2012-08-02 DK DK12741022.3T patent/DK2739615T3/en active
- 2012-08-02 KR KR1020147002515A patent/KR101944686B1/ko active Active
- 2012-08-02 CN CN201610214305.1A patent/CN105837562B/zh active Active
- 2012-08-03 UY UY34239A patent/UY34239A/es unknown
-
2013
- 2013-12-17 IL IL229962A patent/IL229962A/en active IP Right Grant
-
2014
- 2014-01-31 MA MA36719A patent/MA35286B1/fr unknown
- 2014-01-31 CL CL2014000246A patent/CL2014000246A1/es unknown
- 2014-01-31 TN TNP2014000044A patent/TN2014000044A1/en unknown
- 2014-02-03 CO CO14022058A patent/CO6870037A2/es active IP Right Grant
- 2014-02-26 EC ECSP14013221 patent/ECSP14013221A/es unknown
-
2017
- 2017-06-06 CY CY20171100591T patent/CY1119326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| CY1122610T1 (el) | Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| NI201400023A (es) | Derivados de pirrolopirimidina y purina | |
| PE20141308A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20142186A1 (es) | Derivados biciclicos de pirazinona | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| UY36226A (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| PE20170303A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |